ABBV AbbVie Inc.

85.61
-2.1  -2%
Previous Close 87.71
Open 86.8
Price To Book -44.13
Market Cap 128775959754
Shares 1,504,216,327
Volume 5,441,245
Short Ratio 3.92
Av. Daily Volume 6,859,931

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181165405
  2. 8-K - Current report 181155517
  3. 8-K - Current report 181129368
  4. 8-K - Current report 181075865
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181072882

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 20, 2017 - primary endpoint and key secondary endpoints met.
ABT-494 - SELECT-MONOTHERAPY
Rheumatoid arthritis
Phase 3 trial to be initiated 1H 2018.
Risankizumab
Ulcerative colitis
Phase 3 data released April 9, 2018. Primary and secondary endpoints met.
ABT-494 - SELECT-COMPARE
Rheumatoid arthritis
Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-414
Recurrent glioblastoma (rGBM)
Phase 3 top-line released September 11, 2017. Endpoints met but with two patient deaths.
ABT-494 - SELECT-BEYOND
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial initiated July 2016.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 trial planned.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial planned.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2H 2017.
Risankizumab
Crohn’s Disease
Phase 3 data released October 26, 2017 - primary endpoints met. BLA filing announced April 25, 2018.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 3 top-line data released June 7, 2017 - primary endpoints met.
ABT-494 (upadacitinib) - SELECT-NEXT
Rheumatoid arthritis
Phase 3 trial planned for 2018.
Risankizumab
Psoriatic Arthritis
Phase 3 trial initiated late 2017.
ABT-494
Crohn’s Disease
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Phase 3 trial met all endpoints - June 5, 2018. Regulatory filing due 2H 2018.
ABT-494 - SELECT-EARLY
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 data due 2020.
Rova-T (MERU)
First-line Small Cell Lung Cancer
sNDA accepted for priority review - noted October 16, 2018. PDUFA date not given. Estimate 1Q 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
Phase 3 data released October 31, 2018 - PFS primary endpoint met.
Venetoclax
Chronic Lymphocytic Leukemia

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181165405
  2. 8-K - Current report 181155517
  3. 8-K - Current report 181129368
  4. 8-K - Current report 181075865
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181072882
  6. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 181069820
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181068032
  8. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181067969
  9. 8-K - Current report 181058143
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18997182